Literature DB >> 29562308

European cancer mortality predictions for the year 2018 with focus on colorectal cancer.

M Malvezzi1, G Carioli1, P Bertuccio1, P Boffetta2, F Levi3, C La Vecchia4, E Negri5.   

Abstract

Background: We projected cancer mortality statistics for 2018 for the European Union (EU) and its six more populous countries, using the most recent available data. We focused on colorectal cancer. Materials and methods: We obtained cancer death certification data from stomach, colorectum, pancreas, lung, breast, uterus, ovary, prostate, bladder, leukaemia, and total cancers from the World Health Organisation database and projected population data from Eurostat. We derived figures for France, Germany, Italy, Poland, Spain, the UK, and the EU in 1970-2012. We predicted death numbers by age group and age-standardized (world population) rates for 2018 through joinpoint regression models.
Results: EU total cancer mortality rates are predicted to decline by 10.3% in men between 2012 and 2018, reaching a predicted rate of 128.9/100 000, and by 5.0% in women with a rate of 83.6. The predicted total number of cancer deaths is 1 382 000 when compared with 1 333 362 in 2012 (+3.6%). We confirmed a further fall in male lung cancer, but an unfavourable trend in females, with a rate of 14.7/100 000 for 2018 (13.9 in 2012, +5.8%) and 94 500 expected deaths, higher than the rate of 13.7 and 92 700 deaths from breast cancer. Colorectal cancer predicted rates are 15.8/100 000 men (-6.7%) and 9.2 in women (-7.5%); declines are expected in all age groups. Pancreatic cancer is stable in men, but in women it rose +2.8% since 2012. Ovarian, uterine and bladder cancer rates are predicted to decline further. In 2018 alone, about 392 300 cancer deaths were avoided compared with peak rates in the late 1980s.
Conclusion: We predicted continuing falls in mortality rates from major cancer sites in the EU and its major countries to 2018. Exceptions are pancreatic cancer and lung cancer in women. Improved treatment and-above age 50 years-organized screening may account for recent favourable colorectal cancer trends.

Entities:  

Mesh:

Year:  2018        PMID: 29562308     DOI: 10.1093/annonc/mdy033

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  61 in total

Review 1.  [Pancreatic ductal adenocarcinoma].

Authors:  E Gallmeier; T M Gress
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

2.  Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Sandeep Artham; Mir S Adil; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2019-06-14       Impact factor: 5.858

3.  Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer.

Authors:  Giuseppe A Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Int J Clin Oncol       Date:  2019-07-09       Impact factor: 3.402

4.  Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.

Authors:  Pauline Rochefort; Audrey Lardy-Cleaud; Matthieu Sarabi; Françoise Desseigne; Anne Cattey-Javouhey; Christelle de la Fouchardière
Journal:  Oncologist       Date:  2019-06-04

5.  Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Masatoyo Nakajo; Kosei Maemura; Shiho Arima; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

6.  Trends in Mortality Rates for Gastrointestinal Cancers in Fars Province, Iran (2005-2015).

Authors:  Hossein-Ali Nikbakht; Sadaf Sahraian; Haleh Ghaem; Afshan Javadi; Maryam Janfada; Soheil Hassanipour; Ali-Reza Mirahmadizadeh
Journal:  J Gastrointest Cancer       Date:  2020-03

7.  The diagnostic value of a change in bowel habit for colorectal cancer within different age groups.

Authors:  Sofia M McCulloch; Imran Aziz; Annikka V Polster; Andreas-Bernd Pischel; Henrik Stålsmeden; Morteza Shafazand; Mattias Block; Gunnar Byröd; Björn Lindkvist; Hans Törnblom; Börje Jonefjäll; Magnus Simren
Journal:  United European Gastroenterol J       Date:  2019-11-06       Impact factor: 4.623

Review 8.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

Authors:  Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu
Journal:  Circ Res       Date:  2019-09-19       Impact factor: 17.367

Review 9.  MRI-targeted prostate biopsy: the next step forward!

Authors:  Emanuel Darius Cata; Iulia Andras; Teodora Telecan; Attila Tamas-Szora; Radu-Tudor Coman; Dan-Vasile Stanca; Ioan Coman; Nicolae Crisan
Journal:  Med Pharm Rep       Date:  2021-04-29

Review 10.  Atomic force microscopy for revealing micro/nanoscale mechanics in tumor metastasis: from single cells to microenvironmental cues.

Authors:  Mi Li; Ning Xi; Yue-Chao Wang; Lian-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2020-08-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.